Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Phase 2

Active, not recruiting

Conditions: Recurrent Primary Amyloidosis

Interventions: Drug: Dexamethasone
Drug: Cyclophosphamide
Biological: Elotuzumab
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Pharmacological Study

First Posted Date: 2017-08-17

Last Posted Date: 2023-01-25

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 53

Registration Number: NCT03252600

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Levine Cancer Center, Charlotte, North Carolina, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 2 locations

Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP

Phase 3

Conditions: Purpura, Thrombocytopenic, Idiopathic
Immune Thrombocytopenia

Interventions: Drug: Decitabine
Drug: Dexamethasone

First Posted Date: 2017-08-17

Last Posted Date: 2018-08-15

Lead Sponsor: Shandong University

Target Recruit Count: 200

Registration Number: NCT03252457

Locations: 🇨🇳
Qilu hospital, Shandong University, Jinan, Shandong, China

Analgesic Effect of Adductor Canal Block With and Without Dexamethasone for Knee Arthroscopy

Not Applicable

Completed

Conditions: Postoperative Analgesia

Interventions: Drug: Saline Solution
Drug: Dexamethasone

First Posted Date: 2017-08-04

Last Posted Date: 2017-08-04

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT03239314

Surgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence

Phase 4

Completed

Conditions: Keloid

Interventions: Drug: Dexamethasone
Other: surgical excision

First Posted Date: 2017-08-04

Last Posted Date: 2018-11-05

Lead Sponsor: Kasr El Aini Hospital

Target Recruit Count: 146

Registration Number: NCT03239964

Locations: 🇪🇬
KasralainiH, Cairo, Egypt

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Phase 1

Completed

Conditions: AL Amyloidosis

Interventions: Drug: Ixazomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2017-08-02

Last Posted Date: 2022-09-29

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 28

Registration Number: NCT03236792

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Low Dose Aprepitant for Patients Receiving Carboplatin

Phase 2

Terminated

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Aprepitant 125 mg
Drug: Fosaprepitant 115 MG
Drug: Dexamethasone
Drug: Ondansetron 16 MG

First Posted Date: 2017-08-02

Last Posted Date: 2023-11-13

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 15

Registration Number: NCT03237611

Locations: 🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Treatment Modalities of Oral Lichen Planus

Early Phase 1

Conditions: Oral Lichen Planus

Interventions: Drug: Dexamethasone

First Posted Date: 2017-08-02

Last Posted Date: 2017-08-02

Lead Sponsor: University of Faisalabad

Target Recruit Count: 32

Registration Number: NCT03237533

Locations: 🇵🇰
The university of Faisalabad, Faisalābād, Punjab, Pakistan

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Velcade
Drug: Dexamethasone

First Posted Date: 2017-08-01

Last Posted Date: 2024-05-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 213

Registration Number: NCT03234972

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
Peking University First Hospital, Beijing, China

and more 24 locations